Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 115, Issue 11, Pages 1335-1342
Publisher
Springer Nature
Online
2016-10-14
DOI
10.1038/bjc.2016.326
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
- (2017) Gary H. Lyman Journal of the National Comprehensive Cancer Network
- Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review
- (2015) C.N. Frederiks et al. CANCER TREATMENT REVIEWS
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
- (2015) B. P. Schneider et al. CLINICAL CANCER RESEARCH
- Role of cytochrome P4502C8*3(CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity
- (2015) Mi-Young Lee et al. PHARMACOGENOMICS
- Chemotherapy-induced neuropathy: A comprehensive survey
- (2014) N.C. Miltenburg et al. CANCER TREATMENT REVIEWS
- Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
- (2014) J. E. Abraham et al. CLINICAL CANCER RESEARCH
- Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
- (2014) S.W. Lam et al. EUROPEAN JOURNAL OF CANCER
- CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel
- (2013) D. L. Hertz et al. ANNALS OF ONCOLOGY
- CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
- (2013) A.-J. M. de Graan et al. CLINICAL CANCER RESEARCH
- Defining Risks of Taxane Neuropathy: Insights from Randomized Clinical Trials
- (2013) D. Kudlowitz et al. CLINICAL CANCER RESEARCH
- Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy
- (2013) Luis J Leandro-García et al. JOURNAL OF MEDICAL GENETICS
- CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
- (2012) Daniel L. Hertz et al. BREAST CANCER RESEARCH AND TREATMENT
- Regulatory Polymorphisms in -Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
- (2012) L. J. Leandro-Garcia et al. CLINICAL CANCER RESEARCH
- A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
- (2012) R. M. Baldwin et al. CLINICAL CANCER RESEARCH
- Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer
- (2011) Troels K. Bergmann et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
- (2011) Sibylle Loibl et al. BMC CANCER
- Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
- (2011) Troels K. Bergmann et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
- (2011) Yuko Tanabe et al. International Journal of Clinical Oncology
- Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
- (2010) A. Chan et al. ANNALS OF ONCOLOGY
- Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy
- (2010) Dawn L. Hershman et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer
- (2010) T K Bergmann et al. PHARMACOGENOMICS JOURNAL
- Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
- (2010) S Leskelä et al. PHARMACOGENOMICS JOURNAL
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
- (2010) D Wang et al. PHARMACOGENOMICS JOURNAL
- Diagnosis, natural history, and management of Charcot–Marie–Tooth disease
- (2009) Davide Pareyson et al. LANCET NEUROLOGY
- Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
- (2008) Henrik Gréen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started